These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 13740532)

  • 1. Living attenuated measles-virus vaccine in early infancy. Studies of the role of passive antibody in immunization.
    REILLY CM; STOKES J; BUYNAK EB; GOLDNER H; HILLEMAN MR
    N Engl J Med; 1961 Jul; 265():165-9. PubMed ID: 13740532
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of herd immunity in control of measles.
    Black FL
    Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector.
    Kovarik J; Gaillard M; Martinez X; Bozzotti P; Lambert PH; Wild TF; Siegrist CA
    Virology; 2001 Jun; 285(1):12-20. PubMed ID: 11414801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles active and passive immunity in a worldwide perspective.
    Black FL
    Prog Med Virol; 1989; 36():1-33. PubMed ID: 2685909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reimmunization following early immunization with measles vaccine: a prospective study.
    McGraw TT
    Pediatrics; 1986 Jan; 77(1):45-8. PubMed ID: 3940359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity.
    Maldonado YA; Lawrence EC; DeHovitz R; Hartzell H; Albrecht P
    Pediatrics; 1995 Sep; 96(3 Pt 1):447-50. PubMed ID: 7651776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of living attenuated measles-virus vaccine in early infancy.
    STOKES J; REILLY CM; HILLEMAN MR; BUYNAK EB
    N Engl J Med; 1960 Aug; 263():230-3. PubMed ID: 13834839
    [No Abstract]   [Full Text] [Related]  

  • 8. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
    Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
    Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication-incompetent adenoviruses as vectors for protective immunization against measles virus infection.
    Schindler C; Fooks A; Stephenson J; Liebert UG
    Behring Inst Mitt; 1994 Dec; (95):109-15. PubMed ID: 7755504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exaggerated natural measles following attenuated virus immunization.
    St Geme JW; George BL; Bush BM
    Pediatrics; 1976 Jan; 57(1):148-9. PubMed ID: 1246490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of moderate malnutrition on morbidity and antibody response following vaccination with live, attenuated measles virus vaccine.
    McMurray DN; Loomis SA; Casazza LJ; Rey H
    Bull Pan Am Health Organ; 1979; 13(1):52-7. PubMed ID: 427297
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimum age of measles immunization--maternal and transplacentally transmitted measles antibodies in infancy.
    Mohan M; Mehta PK; Sehgal S; Prabhakar AK; Bhargava SK
    Indian Pediatr; 1981 Sep; 18(9):631-5. PubMed ID: 7319611
    [No Abstract]   [Full Text] [Related]  

  • 13. [Studies on immunity to measles. II. Prophylactic and serological studies on the use of live and attenuated measles-virus vaccine].
    Egami T
    Kumamoto Igakkai Zasshi; 1966 May; 40(5):539-62. PubMed ID: 4164172
    [No Abstract]   [Full Text] [Related]  

  • 14. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.
    Dai B; Chen ZH; Liu QC; Wu T; Guo CY; Wang XZ; Fang HH; Xiang YZ
    Bull World Health Organ; 1991; 69(4):415-23. PubMed ID: 1934235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens.
    Pütz MM; Ammerlaan W; Schneider F; Jung G; Muller CP
    Vaccine; 2004 Oct; 22(31-32):4173-82. PubMed ID: 15474707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroconversion after measles vaccination at nine and fifteen months of age.
    Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
    Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques.
    Pasetti MF; Resendiz-Albor A; Ramirez K; Stout R; Papania M; Adams RJ; Polack FP; Ward BJ; Burt D; Chabot S; Ulmer J; Barry EM; Levine MM
    Clin Pharmacol Ther; 2007 Dec; 82(6):672-85. PubMed ID: 17971812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroencephalographic study of children immunized against measles with live attenuated virus vaccine.
    GIBBS FA; GIBBS EL; ROSENTHAL IM
    N Engl J Med; 1961 Apr; 264():800-1. PubMed ID: 13705073
    [No Abstract]   [Full Text] [Related]  

  • 20. Age for measles immunization seroconversion after measles vaccination at 6-8 months of age--a randomized controlled trial.
    Deivanayagam N; Ramamurthy N; Krishnamurthy PV; Shankar VJ; Ashok TP; Nedunchelian K; Mala N; Ahmed SS
    Indian Pediatr; 1990 Nov; 27(11):1171-6. PubMed ID: 2081639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.